Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT‐CHF (European) study with the ASIAN‐HF registry

Author:

Cao Thong Huy123ORCID,Tay Wan Ting4,Jones Donald J.L.135,Cleland John G.F.6,Tromp Jasper47,Emmens Johanna Elisabeth8ORCID,Teng Tiew‐Hwa Katherine4,Chandramouli Chanchal4,Slingsby Oliver Charles123,Anker Stefan D.9,Dickstein Kenneth10,Filippatos Gerasimos11,Lang Chim C.12,Metra Marco13,Ponikowski Piotr14,Samani Nilesh J.12,Van Veldhuisen Dirk J.8,Zannad Faiez15,Anand Inder S.16ORCID,Lam Carolyn S.P.4ORCID,Voors Adriaan A.8ORCID,Ng Leong L.123ORCID

Affiliation:

1. Department of Cardiovascular Sciences, College of Life Sciences University of Leicester Leicester UK

2. National Institute for Health and Care Research Leicester Biomedical Research Centre University Hospitals of Leicester NHS Trust, Glenfield Hospital Leicester UK

3. Leicester van Geest Multi‐OMICS facility University of Leicester Leicester UK

4. National Heart Centre Singapore and Duke–National University of Singapore Singapore Singapore

5. Leicester Cancer Research Centre, University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary University of Leicester Leicester UK

6. British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Health, College of Medical, Veterinary and Life Sciences University of Glasgow Glasgow UK

7. Saw Swee Hock School of Public Health National University of Singapore and the National University Health System Singapore Singapore

8. Department of Cardiology University of Groningen Groningen The Netherlands

9. Division of Cardiology and Metabolism, Department of Cardiology (CVK), and Berlin‐Brandenburg Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) Partner Site Berlin Charité Universitätsmedizin Berlin Berlin Germany

10. University of Bergen Stavanger University Hospital Stavanger Norway

11. Department of Cardiology, Heart Failure Unit, Athens University Hospital Attikon, School of Medicine National and Kapodistrian University of Athens Athens Greece

12. Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School University of Dundee Dundee UK

13. Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University of Brescia Brescia Italy

14. Department of Heart Diseases Wroclaw Medical University and Cardiology Department, Military Hospital Wroclaw Poland

15. Inserm CIC 1433 Université de Lorrain Nancy France

16. Department of Medicine University of Minnesota Medical School and VA Medical Center Minneapolis MN USA

Abstract

AimsWe investigated the prevalence, clinical characteristics, and prognosis of patients with heart failure (HF) with improved ejection fraction (HFimpEF).Methods and resultsWe used data from BIOSTAT‐CHF including patients with a left ventricular ejection fraction (LVEF) ≤40% at baseline who had LVEF re‐assessed at 9 months. HFimpEF was defined as a LVEF >40% and a LVEF ≥10% increase from baseline at 9 months. We validated findings in the ASIAN‐HF registry. The primary outcome was a composite of time to HF rehospitalization or all‐cause mortality. In BIOSTAT‐CHF, about 20% of patients developed HFimpEF, that was associated with a lower primary event rate of all‐cause mortality (hazard ratio [HR] 0.52, 95% confidence interval [CI] 0.28–0.97, p = 0.040) and the composite endpoint (HR 0.46, 95% CI 0.30–0.70, p < 0.001) compared with patients who remained in persistent HF with reduced ejection fraction (HFrEF). The findings were similar in the ASIAN‐HF (HR 0.40, 95% CI 0.18–0.89, p = 0.024, and HR 0.29, 95% CI 0.17–0.48, p < 0.001). Five independently common predictors for HFimpEF in both BIOSTAT‐CHF and ASIAN‐HF were female sex, absence of ischaemic heart disease, higher LVEF, smaller left ventricular end‐diastolic and end‐systolic diameter at baseline. A predictive model combining only five predictors (absence of ischaemic heart disease and left bundle branch block, smaller left ventricular end‐systolic and left atrial diameter, and higher platelet count) for HFimpEF in the BIOSTAT‐CHF achieved an area under the curve of 0.772 and 0.688 in the ASIAN‐HF (due to missing left atrial diameter and platelet count).ConclusionsApproximately 20–30% of patients with HFrEF improved to HFimpEF within 1 year with better clinical outcomes. In addition, the predictive model with clinical predictors could more accurately predict HFimpEF in patients with HFrEF.

Funder

European Commission

Publisher

Wiley

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Improving the rate of heart failure with improved ejection fraction;European Journal of Heart Failure;2024-08-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3